Budesonide for Crohn's in the upper gut
Treatments studied
Part of Digestive system clinical trials.
This trial tests a budesonide liquid that targets inflammation in the esophagus, stomach, and duodenum (upper digestive tract) in children with Crohn's disease. It aims to see if this treatment can reduce inflammation in those areas without strong side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have Crohn's disease diagnosed by standard criteria.
- They must have active inflammation in the upper digestive tract (esophagus, stomach, or duodenum) seen on endoscopy and confirmed by biopsy.
- They must be on a stable Crohn's treatment without changes for at least 2 weeks.
- They cannot have taken steroid pills or inhaled steroids in the last 30 days.
- They cannot have taken certain acid-reducing medications (called PPIs) in the last 30 days.
- They cannot have a current active infection or have had one in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether budesonide extended-release tablets are safe and effective for improving symptoms in children ages 5–17 with active, mild to moderate ulcerative colitis. It also measures how the medicine moves through the body.
This trial studies whether combining a specific diet with an oral steroid called budesonide can calm symptoms in people with mild to moderate ulcerative colitis. It may help reduce inflammation in the colon while building on stable current treatments.
This trial tests different doses of budesonide rectal foam in children and teens (ages 5–17) with active, mild-to-moderate ulcerative colitis limited to the rectum and lowest part of the colon. It looks at safety, how well it works, and how the medicine moves through the body.
This trial tests whether a medicine called budesonide can help people with a type of chronic stomach discomfort that gets worse after meals (functional dyspepsia). If you often feel full or bloated after eating and have had a normal stomach exam, this study may be a good fit for you.
This Phase 3 trial tests guselkumab to treat children with moderately to severely active Crohn’s disease and ongoing inflammation in the bowel. If you qualify, the study will check whether the medicine can improve symptoms and healing, especially in children who did not respond to other treatments.
This study tests whether a specific “exclusion diet” (removing certain foods) added to standard treatment can better control unstable Crohn’s disease in children. It may help reduce inflammation and flare-ups when symptoms are not controlled by usual medicines.
Hear when a new Crohn Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.